VERU · Veru Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 11, 2025; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VERU
this stock
Veru Inc.
|
$46.55M | +27.6% | -58.6% | — | 8.1% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 11, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VERU | +17.2% | +14.7% | +10.1% | +21.9% | +27.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +16.8% | +10.3% | -3.7% | +18.0% | +13.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.